Patents Assigned to Archemix Corp.
-
Patent number: 8207298Abstract: The invention relates to methods for separating or purifying biopolymer conjugated molecules from unconjugated molecules. In particular, methods are described for purifying a PEGylated protein or oligonucleotide from an unPEGylated protein or oligonucleotide, respectively. The methods are quick and efficient separation methods because they do not require gradient chromatography, fractionation of an eluent or analysis of the eluted fractions. Further, the methods increase yield and purity of the biopolymer conjugated molecule.Type: GrantFiled: May 1, 2009Date of Patent: June 26, 2012Assignee: Archemix Corp.Inventors: Paul Hatala, William J. Issa
-
Patent number: 8105813Abstract: Materials and methods are provided for producing aptamer therapeutics having fully modified nucleotide triphosphates incorporated into their sequence.Type: GrantFiled: June 30, 2006Date of Patent: January 31, 2012Assignee: Archemix Corp.Inventors: John L. Diener, Anthony Dominic Keefe, Kristin Thompson, Chunhua Wang, Shuhao Zhu
-
Patent number: 8101385Abstract: Materials and methods are provided for producing aptamer therapeutics having modified nucleotide triphosphates incorporated into their sequence.Type: GrantFiled: December 21, 2007Date of Patent: January 24, 2012Assignee: Archemix Corp.Inventors: Sharon Cload, John L. Diener, Anthony Dominic Keefe, Kristin Thompson
-
Patent number: 7998940Abstract: The invention relates generally to the field of nucleic acids and more particularly to aptamers capable of binding to von Willebrand Factor useful as therapeutics in and diagnostics of thrombotic diseases and/or other diseases or disorders in which von Willebrand Factor mediated platelet aggregation has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to von Willebrand Factor.Type: GrantFiled: January 29, 2009Date of Patent: August 16, 2011Assignee: Archemix Corp.Inventors: John L. Diener, H. A. Daniel Lagasse, Claude Benedict
-
Patent number: 7960102Abstract: Materials and methods of use thereof are presented for the treatment of diabetes and other diseases. Therapeutic compositions including regulated aptamer therapeutic compositions with specificity to components of diabetes disease are presented with methods of administering these therapeutic compositions.Type: GrantFiled: November 30, 2005Date of Patent: June 14, 2011Assignee: Archemix Corp.Inventors: David Epstein, Charles Wilson, John L. Diener
-
Patent number: 7803931Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.Type: GrantFiled: February 14, 2005Date of Patent: September 28, 2010Assignee: Archemix Corp.Inventors: Claude Benedict, John Diener, David Epstein, Dilara Grate, Sara Chesworth Keene, Jeffrey Kurz, Markus Kurz, Thomas Greene McCauley, James Rottman, Kristin Thompson, Charles Wilson, Anna J. Zoltoski
-
Patent number: 7767803Abstract: The present invention provides stabilized, high affinity nucleic acid ligands to PSMA. Methods for the identification and preparation of novel, stable, high affinity ligands to PSMA using the SELEX™ method with 2?-O-methyl substituted nucleic acids, and cell surface SELEX™ are described herein. Also included are methods and compositions for the treatment and diagnosis of disease characterized by PSMA expression, using the described nucleic acid ligands.Type: GrantFiled: March 7, 2006Date of Patent: August 3, 2010Assignee: Archemix Corp.Inventors: John L. Diener, Paul Hatala, Jess Wagner-Whyte, Charles Wilson
-
Publication number: 20100041866Abstract: A compound which can be attached to a solid support and used as a reagent for methods of solid phase synthesis has the following structure: (I) where Ri is selected from hydrogen and C1-C6 alkyl; R2 is selected from hydrogen, hydroxy, and C1-C6 alkoxy, or together R1 and R2 form a single bond; R3, R4, R5 and R6 are the same or different from each other and each represents hydrogen, C1-C6 alkyl, and halogen, or together R3 and R4 with R5 and R6 form an aromatic ring, further wherein the aromatic ring is substituted with one or more X; X is selected from halogen, nitro, amino, and aminocarbonyl; s is 0, 1, 2, or 3, t is 0, 1, 2, or 3, wherein s+t?1; R7 and R8 are the same or different from each other and each represents hydroxy, halogen, hydrogen, C1-C6 alkoxy, oxyacyl, or together R7 and R8 form a carbonyl; Y is selected from a methylene or substituted methylene, nucleoside, nucleotide, protected nucleoside, protected nucleotide, C1-C6 aryl, arylalkyl, heteroalkyl, heterocycle, and heteroaryl; n is 1, 2, 3, 4,Type: ApplicationFiled: March 26, 2007Publication date: February 18, 2010Applicant: ARCHEMIX CORP.Inventors: Paul J. Hatala, Markus Kurz
-
Patent number: 7589073Abstract: The invention relates generally to the field of nucleic acids and more particularly to aptamers capable of binding to von Willebrand Factor useful as therapeutics in and diagnostics of thrombotic diseases and/or other diseases or disorders in which von Willebrand Factor mediated platelet aggregation has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to von Willebrand Factor.Type: GrantFiled: January 12, 2006Date of Patent: September 15, 2009Assignee: Archemix Corp.Inventors: John L. Diener, H. A. Daniel Lagassé, Claude Benedict
-
Patent number: 7579456Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.Type: GrantFiled: February 14, 2006Date of Patent: August 25, 2009Assignee: Archemix Corp.Inventors: Claude Benedict, David Epstein, Dilârâ McCauley, Jeffrey Kurz, Markus Kurz, Thomas Greene McCauley, James Rottman, Charles Wilson
-
Patent number: 7579450Abstract: The invention discloses aptamers capable of binding to Immunoglobulin E (“IgE”) useful as therapeutics in and diagnostics of atopic disease and/or other diseases or disorders in which IgE has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to IgE.Type: GrantFiled: April 26, 2005Date of Patent: August 25, 2009Assignee: Archemix Corp.Inventors: Paula Burmeister, Sharon Cload, John L. Diener, Anthony Dominic Keefe, Sara Chesworth Keene, Markus Kurz, H. A. Daniel Lagassé, Harold Nicholas Marsh, Pooja Sawhney, Chunhua Wang
-
Publication number: 20090203766Abstract: The invention relates to the formulation, dosing, administration and use of an aptamer antagonist therapeutic that binds to von Willebrand Factor.Type: ApplicationFiled: May 30, 2008Publication date: August 13, 2009Applicant: Archemix Corp.Inventors: James Gilbert, Renta Hutabarat, Robert G. Schaub
-
Patent number: 7566701Abstract: The invention relates generally to the field of nucleic acids and more particularly to aptamers capable of binding to von Willebrand Factor useful as therapeutics in and diagnostics of thrombotic diseases and/or other diseases or disorders in which von Willebrand Factor mediated platelet aggregation has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to von Willebrand Factor.Type: GrantFiled: September 7, 2005Date of Patent: July 28, 2009Assignee: Archemix Corp.Inventors: John L. Diener, H. A. Daniel Lagassé, Claude Benedict
-
Publication number: 20090149643Abstract: The invention relates generally to the field of nucleic acids and more particularly to aptamers capable of binding to von Willebrand Factor useful as therapeutics in and diagnostics of thrombotic diseases and/or other diseases or disorders in which von Willebrand Factor mediated platelet aggregation has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to von Willebrand Factor.Type: ApplicationFiled: January 29, 2009Publication date: June 11, 2009Applicant: Archemix Corp.Inventors: John L. Diener, H.A. Daniel Lagasse, Claude Benedict
-
Patent number: 7538211Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.Type: GrantFiled: December 22, 2005Date of Patent: May 26, 2009Assignee: Archemix Corp.Inventors: Claude Benedict, John Diener, David Epstein, Dilara Grate, Sara Chesworth Keene, Jeffrey Kurz, Markus Kurz, Thomas Greene McCauley, James Rottman, Kristin Thompson, Charles Wilson, Anna J. Zoltoski
-
Patent number: 7125660Abstract: Methods for engineering a nucleic acid sensor molecule are provided. Biosensors comprise a plurality of nucleic acid sensor molecules labeled with a first signaling moiety and a second signaling moiety. The nucleic acid sensor molecules recognizes target molecules which do not naturally bind to DNA. Binding of a target molecule to the sensor molecules triggers a change in the proximity of the signaling moieties which leads to a change in the optical properties of the nucleic acid sensor molecules on the biosensor. Reagents and systems for performing the method are also provided. The method is useful in diagnostic applications and drug optimization.Type: GrantFiled: August 9, 2002Date of Patent: October 24, 2006Assignee: Archemix Corp.Inventors: Martin Stanton, David Epstein, Nobuko Hamaguchi, Markus Kurz, Tony Keefe, Charles Wilson, Dilara Grate, Kristin A. Marshall, Thomas G. McCauley, Jeffrey C. Kurz